Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | HINT1 | P49773 | 8/20 | 0.34 |
| ▸ | KRAS | P01116 | 4/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15878701 | 0.99 | HPGD (0.36) | HPGDTAAR1TYMPTAS1R3TAS1R1 | |
| SCHEMBL2215519 | 0.95 | HPGD (0.35) | HPGDTAAR1TYMPTAS1R3TAS1R1 | |
| SCHEMBL3905624 | 0.94 | HPGD (0.37) | HPGDTAAR1TYMPTAS1R3TAS1R1 | |
| SCHEMBL2108084 | 0.94 | HPGD (0.38) | HPGDTAAR1TYMPTAS1R3TAS1R1 | |
| SCHEMBL2106148 | 0.89 | TYMP (0.42) | HPGDTAAR1TYMPTAS1R3TAS1R1 | |
| SCHEMBL15841440 | 0.88 | TYMP (0.41) | HPGDTAAR1TYMPTAS1R3TAS1R1 | |
| SCHEMBL1317492 | 0.84 | CARM1 (0.34) | TYMP | |
| SCHEMBL2109084 | 0.83 | TRDMT1 (0.36) | TYMP | |
| SCHEMBL6443389 | 0.82 | HPGD (0.37) | HPGDTAAR1TYMPTAS1R3TAS1R1 | |
| SCHEMBL15879332 | 0.82 | TRDMT1 (0.36) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1995253-B1 | METHOD FOR DETACHING PROTECTING GROUP ON NUCLEIC ACID | NIPPON SHINYAKU CO LTD (JP) | 2016-12-21 | — | — | EP | disclosed |
| EP-2551273-A1 | PHOSPHORYLATION REAGENT | The University of Tokyo (JP) | 2013-01-30 | — | — | EP | disclosed |
| US-20120322993-A1 | Phosphorylation Reagent | NIPPON SHINYAKU CO., LTD. (JP) | 2012-12-20 | — | — | US | disclosed |
| EP-1795536-B1 | PHOSPHORAMIDITE COMPOUND AND METHOD FOR PRODUCING OLIGO-RNA | NIPPON SHINYAKU CO LTD (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8158775-B2 | Method for detaching protecting group on nucleic acid | NIPPON SHINYAKU CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20090312534-A1 | METHOD FOR REMOVAL OF NUCLEIC ACID-PROTECTING GROUP | NIPPON SHINYAKU CO., LTD. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090149645-A1 | METHOD FOR DETACHING PROTECTING GROUP ON NUCLEIC ACID | NIPPON SHINYAKU CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20090137790-A1 | METHOD OF CAPPING OLIGONUCLEIC ACID | NIPPON SHINYAKU CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2017282-A1 | METHOD OF CAPPING OLIGONUCLEIC ACID | Nippon Shinyaku Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-1995252-A1 | METHOD FOR REMOVAL OF NUCLEIC ACID-PROTECTING GROUP | Nippon Shinyaku Co., Ltd. (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1995253-A1 | METHOD FOR DETACHING PROTECTING GROUP ON NUCLEIC ACID | Nippon Shinyaku Co., Ltd. (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-20070282097-A1 | Phosphoramidite Compound And Method For Producing Oligo-Rna | NIPPON SHINYAKU CO., LTD. (JP) | 2007-12-06 | — | — | US | disclosed |
| EP-1795536-A1 | PHOSPHORAMIDITE COMPOUND AND METHOD FOR PRODUCING OLIGO-RNA | Nippon Shinyaku Co., Ltd. (JP) | 2007-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312534-A1 | METHOD FOR REMOVAL OF NUCLEIC ACID-PROTECTING GROUP | NSUN2, RNASEH1, RNASE1 | HPGD 2241/4885TAAR1 4221/4885TYMP 321/4885 |
| US-20090137790-A1 | METHOD OF CAPPING OLIGONUCLEIC ACID | RNGTT, DUT, ADAR | HPGD 3144/4885TAAR1 3438/4885TYMP 122/4885 |
| US-20070282097-A1 | Phosphoramidite Compound And Method For Producing Oligo-Rna | NSUN2, NSUN3, XRN2 | HPGD 4533/4885TAAR1 2737/4885TYMP 485/4885 |
| US-20120322993-A1 | Phosphorylation Reagent | CSNK2A2, CSNK2A1, CSNK2B | HPGD 4351/4885TAAR1 3762/4885TYMP 2356/4885 |
| US-20090149645-A1 | METHOD FOR DETACHING PROTECTING GROUP ON NUCLEIC ACID | DNASE1, DNASE1L3, NSUN2 | HPGD 2390/4885TAAR1 3814/4885TYMP 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.